» Articles » PMID: 37272582

Mechanisms Regulating Vascular and Lymphatic Regeneration in the Heart After Myocardial Infarction

Overview
Journal J Pathol
Specialty Pathology
Date 2023 Jun 5
PMID 37272582
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial infarction, caused by a thrombus or coronary vascular occlusion, leads to irreversible ischaemic injury. Advances in early reperfusion strategies have significantly reduced short-term mortality after myocardial infarction. However, survivors have an increased risk of developing heart failure, which confers a high risk of death at 1 year. The capacity of the injured neonatal mammalian heart to regenerate has stimulated extensive research into whether recapitulation of developmental regeneration programmes may be beneficial in adult cardiovascular disease. Restoration of functional blood and lymphatic vascular networks in the infarct and border regions via neovascularisation and lymphangiogenesis, respectively, is a key requirement to facilitate myocardial regeneration. An improved understanding of the endogenous mechanisms regulating coronary vascular and lymphatic expansion and function in development and in adult patients after myocardial infarction may inform future therapeutic strategies and improve translation from pre-clinical studies. In this review, we explore the underpinning research and key findings in the field of cardiovascular regeneration, with a focus on neovascularisation and lymphangiogenesis, and discuss the outcomes of therapeutic strategies employed to date. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Citing Articles

Recent Insights into Endogenous Mammalian Cardiac Regeneration Post-Myocardial Infarction.

Fiorino E, Rossin D, Vanni R, Aubry M, Giachino C, Rastaldo R Int J Mol Sci. 2024; 25(21).

PMID: 39519298 PMC: 11546116. DOI: 10.3390/ijms252111747.


Platelet-Rich Plasma for Heart Cell Regeneration Post-myocardial Infarction: A Propitious Therapeutic Approach.

Navab R, Haward R, Chacko J, Haward R Cureus. 2024; 16(1):e51951.

PMID: 38333505 PMC: 10852202. DOI: 10.7759/cureus.51951.


Small but strong: the emerging role of small nucleolar RNA in cardiovascular diseases.

Sun X, Wang G, Luo W, Gu H, Ma W, Wei X Front Cell Dev Biol. 2023; 11:1292925.

PMID: 38033868 PMC: 10682241. DOI: 10.3389/fcell.2023.1292925.

References
1.
Wysocka M, Pietraszek-Gremplewicz K, Nowak D . The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer. Front Physiol. 2018; 9:557. PMC: 5974534. DOI: 10.3389/fphys.2018.00557. View

2.
Haubner B, Adamowicz-Brice M, Khadayate S, Tiefenthaler V, Metzler B, Aitman T . Complete cardiac regeneration in a mouse model of myocardial infarction. Aging (Albany NY). 2013; 4(12):966-77. PMC: 3615162. DOI: 10.18632/aging.100526. View

3.
Liao Z, Chen Y, Duan C, Zhu K, Huang R, Zhao H . Cardiac telocytes inhibit cardiac microvascular endothelial cell apoptosis through exosomal miRNA-21-5p-targeted silencing to improve angiogenesis following myocardial infarction. Theranostics. 2021; 11(1):268-291. PMC: 7681094. DOI: 10.7150/thno.47021. View

4.
Losordo D, Vale P, Hendel R, Milliken C, Fortuin F, Cummings N . Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002; 105(17):2012-8. DOI: 10.1161/01.cir.0000015982.70785.b7. View

5.
Kruger-Genge A, Blocki A, Franke R, Jung F . Vascular Endothelial Cell Biology: An Update. Int J Mol Sci. 2019; 20(18). PMC: 6769656. DOI: 10.3390/ijms20184411. View